Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83831-0102-08 83831-0102 Docetaxel DOCIVYX 80.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0103-16 83831-0103 Docetaxel DOCIVYX 160.0 mg/16mL Chemotherapy Antimitotic Agent Taxane Intravenous May 9, 2024 In Use
83831-0104-05 83831-0104 Palonosetron Posfrea 0.075 mg/1.5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 Sep 30, 2024 No Longer Used
83831-0105-01 83831-0105 Palonosetron Posfrea 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 In Use
83831-0111-01 83831-0111 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0112-01 83831-0112 Pemetrexed dipotassium PEMETREXED DIPOTASSIUM 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0116-01 83831-0116 Cyclophosphamide Cyclophosphamide 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug 1, 2024 In Use
83831-0117-02 83831-0117 Cyclophosphamide Cyclophosphamide 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug 1, 2024 In Use
83831-0118-04 83831-0118 Cyclophosphamide Cyclophosphamide 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Aug 1, 2024 In Use
83831-0119-01 83831-0119 Cyclophosphamide Frindovyx 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0120-02 83831-0120 Cyclophosphamide Frindovyx 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0121-04 83831-0121 Cyclophosphamide Frindovyx 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0122-01 83831-0122 Gemcitabine AVGEMSI 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jul 18, 2025 In Use
83831-0123-01 83831-0123 Gemcitabine AVGEMSI 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug 3, 2025 In Use
83831-0124-01 83831-0124 Gemcitabine AVGEMSI 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug 3, 2025 In Use
83831-0131-01 83831-0131 Pemetrexed AXTLE 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0132-01 83831-0132 Pemetrexed AXTLE 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
83831-0134-01 83831-0134 Leuprolide acetate LUTRATE DEPOT 22.5 mg/2ml Hormonal Therapy GnRH Agonist Intramuscular Mar 26, 2025 In Use
83831-0140-02 83831-0140 CARBOplatin KYXATA 20.0 mg/2mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 11, 2025 In Use
83831-0141-08 83831-0141 CARBOplatin KYXATA 80.0 mg/8mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 11, 2025 In Use
83831-0142-50 83831-0142 CARBOplatin KYXATA 500.0 mg/50mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Aug 11, 2025 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0104-30 83858-0104 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use

Found 11765 results — Export these results